UK drug reform: is it time to rethink drug policy?

Monday, 3rd October | 12.45 – 13.45

What are the benefits of broadening drug policy beyond the misuse of drugs? Psilocybin’s proven to treat cluster migraines. Cannabis has been shown to treat Alzheimer’s and multiple mental health conditions. Is now the time to move to more evidence-based drug policy, or are these still hazardous substances that pose a risk to public health?

Chris Snowdon (Chair), Head of lifestyle economics, Institute of Economic Affairs

Tara Austin, Consulting partner, Ogilvy Behavioural Science Practice

Crispin Blunt MP, Chairman of the Conservative Drug Policy Reform Group

Matthew Lesh, Head of Public Policy, Institute of Economic Affairs